Metabolic syndrome in patients with stage 3-4 chronic kidney disease (CKD) is associated with an increased risk of end-stage renal disease (ESRD) but not death, researchers concluded.
A team at the Cleveland Clinic led by Sankar D. Navaneethan, MD, of the clinic’s Glickman Urological and Kidney Institute, studied 25,868 patients with stages 3-4 CKD, of whom 15,605 (60%) had metabolic syndrome. After adjusting for multiple potential confounders, metabolic syndrome was associated with a 33% increased risk for ESRD but not death during a 2.3-year follow-up period, according to findings published online ahead of print in the Clinical Journal of the American Society of Nephrology. In addition, among the individual components of metabolic syndrome, impair glucose metabolism, elevated triglycerides, and hypertension were associated with an increased risk of ESRD but low high-density lipoprotein cholesterol and impaired glucose metabolism were associated with an increased risk of death.
Study findings have significant clinical importance, the authors noted, because individual components of metabolic syndrome, metabolic syndrome itself, and CKD in the U.S. population and around the world are increasing.